Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer
- 18.06.2020
- Case Report
- Verfasst von
- Francesco Paciullo
- Loredana Bury
- Paolo Gresele
- Erschienen in
- International Journal of Hematology | Ausgabe 5/2020
Abstract
Chemotherapy is the mainstay of treatment for advanced pancreatic cancer however, due to possible myelotoxicity, it is used with caution in patients with thrombocytopenia, especially when severe. TPO-receptor agonists have been employed for chemotherapy-induced thrombocytopenia, however treatment with TPO-receptor agonists to allow chemotherapy in patients with inherited thrombocytopenia has not been reported so far. We report the first successful use of eltrombopag to prevent chemotherapy-induced thrombocytopenia in a patient with MHY9-related disorder and pancreatic cancer. Treatment with eltrombopag allowed to attain a safe and stable platelet count for several months sufficient to permit chemotherapy and to allow the patient to undergo endoscopic placement of a biliary stent with no bleeding complications.
Anzeige
- Titel
- Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer
- Verfasst von
-
Francesco Paciullo
Loredana Bury
Paolo Gresele
- Publikationsdatum
- 18.06.2020
- Verlag
- Springer Singapore
- Erschienen in
-
International Journal of Hematology / Ausgabe 5/2020
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774 - DOI
- https://doi.org/10.1007/s12185-020-02918-6
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.